Atlas Trials

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Clinical trial NCT01200329 · COMPLETED

Trial details

NCT number
NCT01200329
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoma
Start date
2011-06-01
Primary completion
2018-12-06
Enrollment
81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.